IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Autor: Metz R; New Link Genetics Corporation, Ames, IA, USA., Smith C; Lankenau Institute for Medical Research, Wynnewood, PA, USA., DuHadaway JB; Lankenau Institute for Medical Research, Wynnewood, PA, USA., Chandler P; Immunotherapy Center, Georgia Regents University, Augusta, GA, USA., Baban B; Immunotherapy Center, Georgia Regents University, Augusta, GA, USA., Merlo LMF; Lankenau Institute for Medical Research, Wynnewood, PA, USA., Pigott E; Lankenau Institute for Medical Research, Wynnewood, PA, USA., Keough MP; Lankenau Institute for Medical Research, Wynnewood, PA, USA., Rust S; New Link Genetics Corporation, Ames, IA, USA., Mellor AL; Immunotherapy Center, Georgia Regents University, Augusta, GA, USA., Mandik-Nayak L; Lankenau Institute for Medical Research, Wynnewood, PA, USA.; Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, USA., Muller AJ; Lankenau Institute for Medical Research, Wynnewood, PA, USA.; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Prendergast GC; Lankenau Institute for Medical Research, Wynnewood, PA, USA.; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pathology, Anatomy and Cell Biology, Jefferson Medical School, Thomas Jefferson University, Philadelphia, PA, USA.

Publikováno v: International immunology [Int Immunol] 2019 Mar 05; Vol. 31 (3), pp. 181-182.

Ido2 Deficiency Exacerbates Motor Impairment and Reduces Aryl Hydrocarbon Receptor Activity through Decreased Kynurenine in a Chronic Demyelinating Mouse Model.

Autor: Kunisawa K; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan. kunisawa@fujita-hu.ac.jp., Hara M; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan., Yoshidomi K; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan., Kon Y; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan., Yamamoto Y; Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Aichi, Japan., Fujigaki S; Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Aichi, Japan., Wulaer B; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan.; Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Aichi, Japan., Kosuge A; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan., Tanabe M; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan.; Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Science, Aichi, Japan., Saitoh S; Department of Biomedical Molecular Sciences, Fujita Health University School of Medicine, Aichi, Japan., Takahashi K; Department of Biomedical Molecular Sciences, Fujita Health University School of Medicine, Aichi, Japan., Saito K; Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Aichi, Japan.; Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Science, Aichi, Japan.; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan., Nabeshima T; Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Science, Aichi, Japan.; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan., Mouri A; Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Science, Aichi, 470-1192, Japan. mouri@fujita-hu.ac.jp.; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan. mouri@fujita-hu.ac.jp.

Publikováno v: Molecular neurobiology [Mol Neurobiol] 2024 Jun 03. Date of Electronic Publication: 2024 Jun 03.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative Evaluation of Veriflow® Listeria monocytogenes to USDA and AOAC Culture Based Methods for the Detection of Listeria monocytogenes in Food.

Autor: Joelsson AC; Invisible Sentinel, Inc., 3711 Market St, Suite 910, Philadelphia, PA 19104, USA., Brown AS, Puri A, Keough MP, Gaudioso ZE, Siciliano NA, Snook AE

Publikováno v: Journal of AOAC International [J AOAC Int] 2015 Sep-Oct; Vol. 98 (5), pp. 1325-34.

Matrix Protein of Vesicular Stomatitis Virus Targets the Mitochondria, Reprograms Glucose Metabolism, and Sensitizes to 2-Deoxyglucose in Glioblastoma.

Autor: Zhou, Yi, Li, Yongzhong, Chenm, Jing, Mei, Kai, Kang, Mingxiang, Chen, Ping, Li, Qiu

Publikováno v: Human Gene Therapy; Oct2024, Vol. 35 Issue 19/20, p838-854, 17p